Are you Dr. Lakhani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 43 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5800 Foremost Dr SE Ste 100
Grand Rapids, MI 49546Phone+1 616-954-5554- Is this information wrong?
Summary
- Dr. Nehal Lakhani, MD is an oncologist in Grand Rapids, Michigan. He is currently licensed to practice medicine in Michigan and Pennsylvania. He is affiliated with Trinity Health Grand Rapids Hospital, Corewell Health - Butterworth Hospital, and University of Michigan Health-Sparrow Carson.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Spectrum Health/Michigan State UniversityResidency, Internal Medicine, 2005 - 2008
Baroda Medical CollegeClass of 2000
Certifications & Licensure
MI State Medical License 2005 - 2026
PA State Medical License 2011 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013
Clinical Trials
- Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 Nov 01
- BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
- A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) Start of enrollment: 2017 Feb 03
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsFirst-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.Nehal J Lakhani, Drew Rasco, Hengbang Wang, Lichuang Men, Eric Liang, Tommy Fu, Mary C Collins, Ping Min, Yan Yin, Matthew S Davids, Dajun Yang, Yifan Zhai> ;Clinical Cancer Research. 2024 Feb 1
- 1 citationsPreclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.Vivek Subbiah, Sant P Chawla, Anthony P Conley, Breelyn A Wilky, Anthony Tolcher, Nehal J Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim...> ;Clinical Cancer Research. 2023 Aug 15
- 53 citationsDual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.Charu Aggarwal, Amy Prawira, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan P Zandberg, Arash Rezazadeh K...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
- Join now to see all
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingMay 25th, 2023- (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination TherapiesMay 31st, 2020
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid TumorsNovember 7th, 2018- Join now to see all
Other Languages
- Hindi
Hospital Affiliations
University of Michigan Health-Sparrow CarsonCarson City, Michigan
Corewell Health Gerber HospitalFremont, Michigan
Corewell Health - Butterworth HospitalGrand Rapids, Michigan
Trinity Health Grand Rapids HospitalGrand Rapids, Michigan
